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Abstract 
Heart failure with preserved ejection fraction (HFpEF), a major public health 
problem with high morbidity and mortality, remains difficult to manage due to a lack of 
effective treatment options. Although HFpEF is a heterogeneous clinical syndrome, 
elevated left atrial (LA) pressure—either at rest or with exertion—is a common factor 
among all forms of HFpEF and one of the primary reasons for dyspnea and exercise 
intolerance in these patients. Based on clinical experience with congenital interatrial 
shunts in mitral stenosis, it has been hypothesized that the creation of a left-to-right 
interatrial shunt to decompress the LA (without compromising left ventricular filling or 
forward cardiac output) is a rational non-pharmacological strategy for alleviating 
symptoms in patients with HFpEF. A novel trans-catheter interatrial shunt device 
(IASD) has been developed and evaluated in patients with HFpEF in single-arm, non-
blinded clinical trials. These studies have demonstrated the safety and potential 
efficacy of the device. However, a randomized, placebo-controlled evaluation of the 
device is required to further evaluate its safety and efficacy in patients with HFpEF. In 
this article, we give the rationale for a therapeutic IASD in HFpEF, and we describe the 
design of REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I), 
the first randomized controlled trial of a device-based therapy to reduce LA pressure in 
HFpEF.  
ClinicalTrials.gov identifier: NCT02600234 (https://clinicaltrials.gov/ct2/show/NCT02600234) 
Key words: randomized controlled trial; diastolic heart failure; devices for heart failure; 
left atrial pressure; intervention 
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Background 
 
 
Prevalence of heart failure with preserved left ventricular ejection fraction 
(HFpEF) 
More than one-half of people with heart failure (HF) have a preserved left ventricular 
ejection fraction (HFpEF).1,2 Patients with HFpEF, commonly referred to as diastolic 
HF, have symptoms and/or signs of HF and a left ventricular ejection fraction (LVEF) 
>40-50%. The prevalence of HFpEF exceeds 3 million in the US alone and its 
prevalence appears to be increasing due to factors such as increased diagnostic 
awareness and greater longevity. The prognosis for patients hospitalized with HFpEF is 
poor, worsens with increasing age, and has not improved over time.3 Epidemiology 
studies have shown similar mortality rates in HF with reduced EF (HFrEF) and HFpEF; 
one-year mortality is 26% in HFrEF compared with 22% in HFpEF.4,5  While 
pharmacological treatments may improve symptoms and reduce mortality in patients 
with chronic HFrEF,6,7 there are currently no approved or evidence based effective 
pharmacotherapies with similar benefits for HFpEF.8-11  
 
Pathophysiology of exercise intolerance in HFpEF 
The general lack of therapeutic responsiveness to neurohormonal therapies and other 
lines of evidence indicate that the underlying pathophysiology in HFpEF is different 
from that of HFrEF. While HFpEF is a complex clinical syndrome of uncertain etiology 
with several contributing factors,12 an increase in left atrial (LA) pressure is a common 
feature of this syndrome and a central cause of debilitating symptoms. Breathlessness, 
exercise intolerance, and fatigue are the characteristic symptoms of the chronic HFpEF 
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syndrome, and are largely attributable to elevated pulmonary venous pressure at rest 
and/or with exercise.  
 
Atrial shunts for left atrial decompression in HFpEF 
Based on clinical experience with naturally occurring interatrial shunts, it has been 
hypothesised that creating a controlled left-to-right interatrial shunt to allow LA 
decompression without compromising left ventricular filling or forward cardiac output, is 
a rational non-pharmacological strategy for alleviating symptoms in patients with 
HFpEF. Furthermore, reports of the natural history of congenital atrial septal defect 
(ASD) suggests that small atrial shunts have no important long-term impact on cardiac 
function.13-15 On the contrary, the protection from LA pressure overload afforded by an 
incidental ASD in patients with mitral stenosis is well described as the Lutembacher 
syndrome16,17 and strokes due to paradoxical embolism are rare.18 
 
We have therefore developed a novel trans-catheter interatrial shunt device (IASD) for 
the treatment of HFpEF.  The IASD is an implant that creates and maintains an atrial 
septal communication. Neither the use of transseptal puncture for device delivery, nor 
the placement of an atrial septal implant are by themselves unusual.  Transseptal 
puncture devices and techniques are widely available and well established.19,20 Atrial 
septal defect closure devices have been in wide use for decades and the techniques 
for implantation and post implantation management are widely used.21 
 
To model the hemodynamic impact of creating such a shunt we reported the theoretical 
acute hemodynamic effects of this approach using a validated cardiovascular 
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simulation.22 Rest and exercise hemodynamic data from two previous independent 
studies of patients with HFpEF were simulated, and the theoretical acute effects of a 
shunt between the right and left atria were determined. The 8 mm diameter interatrial 
shunt acutely lowered PCWP by 3 mmHg under simulated resting conditions and by 11 
mmHg under simulated peak exercise conditions. The interatrial shunt reduced left-
sided cardiac output only slightly with a marked reduction in PCWP. This computer 
simulation suggested that an IASD approach may reduce PCWP while allowing cardiac 
output and heart rate to rise during exercise, potentially resulting in ability to exercise 
longer and reduce the propensity for heart failure exacerbations. This hypothesis is 
supported by clinical observations in patients with Lutembacher syndrome and the 
relative absence of adverse long-term effects in patients with small congenital ASD. 
   
Early results from IASD implants in HFpEF patients 
The IASD has been evaluated in patients with HFpEF in single-arm, non-blinded 
clinical trials.  A pilot, non-randomized, single-arm evaluation of the Corvia Medical 
System with permanent implantation in patients with HFpEF has been completed.23,24 
The primary outcome measure was serious adverse device events through 1-month 
post implant. The key inclusion criteria were at least one HF hospitalization within the 
past 12 months, or persistent NYHA Class III for at least 3 months, age ≥ 40 years, 
LVEF ≥45%. After patients were discharged from the hospital they were followed-up to 
12 months. Eleven patients (6 men and 5 women, mean age 70.5 years) were enrolled 
and completed the study. The study demonstrated the safety and performance of the 
device. At one year, NYHA class and quality of life (Minnesota Living with Heart Failure 
Questionnaire) were improved in 73% and 91% compared to baseline respectively. 
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There were no deaths, cerebrovascular or systemic embolic events. The rate of HF 
hospitalization was reduced compared to the prior year. Unidirectional left-to-right flow 
through the device at rest was demonstrated in all patients in whom analysis was 
possible (9/9).  
 
After the pilot study, the REDUCE LAP-HF Study was performed.25 This was a 
prospective, 6-month, open-label, non-randomized, multicenter study to assess the 
safety and performance of the device in up to 100 HF patients with elevated LA 
pressure who remained symptomatic despite appropriate medical management. 
Enrolment has recently been completed. Patients will be followed for three years. The 
primary safety endpoint is the percentage of subjects who experience MACCE defined 
as death, stroke, MI, or who require implant removal cardiac surgery at 6 months from 
day of implant. 
 
These studies have demonstrated the safety and potential efficacy of the device. 
However, a randomized, placebo-controlled evaluation of the device is now required to 
further evaluate its safety, effectiveness, and efficacy in patients with HFpEF.   
 
Randomized evaluation of the mechanistic effect of IASD in HFpEF: the REDUCE 
LAP-HF I Trial 
Given the unmet needs of patients with HFpEF, and the failure to show effectiveness of 
several pharmacotherapies for this condition, a novel, device-based treatment to 
reduce LA pressure could be a major advance in the care of patients with HFpEF. 
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Accordingly, we have designed a prospective, randomized, placebo-controlled, clinical 
trial to evaluate a transcatheter interatrial shunt for patients with HF and preserved or 
mildly reduced LV ejection fraction. Here we describe the device, study design, and 
inclusion/exclusion criteria for the trial, the REDUCE Elevated Left Atrial Pressure in 
Patients with Heart Failure I (ClinicalTrials.gov NCT02600234), which will be the first 
randomized evaluation of a device-based therapy to reduce LA pressure in patients 
with HFpEF.  
 
 
IASD Device description 
The IASD System II implant (Corvia Medical, Tewksbury, MA) consists of a one-piece 
self-expanding metal cage that has a double-disc design with an opening (barrel) in the 
center (Figure 1).  It is available in one size.  The implant is radiopaque and echogenic 
to allow for imaging during the implantation procedure.  Each side of the implant is 
multi-legged (9 legs/side), and the LA side has a radiopaque marker at the end of each 
leg.  The LA side of the implant is flat to allow the legs to rest flush against the LA wall, 
thereby minimizing the LA profile of the deployed implant.  The RA side is curved to 
accommodate variable septal wall thicknesses, with only the leg ends contacting the 
RA wall. The expanded external diameter of each disc is 19.4 mm.  The inner diameter 
of the barrel in the center of the fully expanded implant is 8 mm.  
 
The delivery system is designed to deploy the implant at the target location across the 
atrial septum (Figure 2, 3).  The implant comes pre-loaded onto the distal tip of the 
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inner catheter of the delivery system. Implant deployment is achieved by retracting the 
outer catheter to release the implant legs and barrel in a controlled stepwise manner.  
 
 
REDUCE LAP-HF I Trial: Study design and objectives 
The primary objective of this clinical trial is to evaluate the peri-procedural safety and 
potential effectiveness (mechanistic effect) of implanting the IASD System II in heart 
failure patients with an LV ejection fraction >40% and elevated left sided filling 
pressures who remain symptomatic despite optimal guideline-directed medical therapy 
(GDMT).26  
The trial is a multicenter, prospective, randomized, controlled, single (patient) blinded 
trial, with non-implant control group and 1:1 randomization. Patients are randomized 
following the study-related qualification procedures (Figure 4), including supine bicycle 
exercise testing during right heart catheterization, to ensure that patients meet 
hemodynamic criteria, namely an elevated pulmonary capillary wedge pressure 
(PCWP) and a gradient between PCWP and right atrial pressure (RAP).  Afterwards, 
eligible patients will be randomized to the treatment or control group. Patient 
randomization will be study wide via the Interactive Web Response System (IWRS). All 
patients will be sedated, and both treatment and control arm patients will undergo 
femoral venous access after randomization.  
Patients randomized to the treatment arm will undergo a transseptal puncture and 
IASD System II implantation guided by fluoroscopy and intracardiac echocardiography. 
Patients randomized to the control arm will undergo intracardiac echocardiography, 
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with examination of the atrial septum and LA appendage.  
Patients randomized to the control arm who still meet the inclusion criteria will be 
allowed to crossover to the treatment arm at ≥ 12 months after the baseline procedure. 
All patients initially randomized and all patients receiving the device will be followed for 
5 years. 
Patient blinding will include sedation, earphones with music to preclude the patient from 
hearing the procedural discussions, and blindfolding, or the use of opaque screens to 
prevent the participant from viewing the imaging screens. Each site will assign blinded 
and un-blinded staff to facilitate unbiased patient assessments through 12 months of 
follow-up. Research staff will be instructed to maintain patient blinding. The physicians 
managing the randomized patients and research staff involved in conducting selected 
post randomization evaluations, including the hemodynamic and cardiopulmonary 
exercise testing (CPET) core laboratories, will be blinded to study arm.  
After treatment, device implanted patients will be treated with clopidogrel for 6 months 
(dose determined per institutional standards) and aspirin 75-81 mg p.o. daily 
indefinitely and control arm patients will be treated with aspirin 75-81 mg p.o. daily for 
one year.  The informed consent states that’s patients may receive one or two 
antiplatelet agents post procedure. Patients with an indication for oral anticoagulation 
and/or antiplatelet therapy for a pre-existing condition will continue the same regimen 
following the procedure.  
 
REDUCE LAP-HF I Trial: Patient population 
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Up to 60 subjects at up to 20 investigational sites in the U.S., and up to 8 
investigational sites outside the US, will be enrolled. From the 60 subjects, 40 patients 
with HFpEF (LVEF >40%) who have elevated left sided filling pressures during 
exercise and who are symptomatic despite optimal GDMT will be included in the 
randomized trial (Table 1). The inclusion and exclusion criteria are detailed in Table 2. 
Key inclusion criteria include documented chronic symptomatic HF; LV ejection fraction 
≥ 40%; and elevated LA pressure with a gradient compared to RAP documented by 
end-expiratory PCWP during supine bike exercise ≥ 25 mmHg, and grater than RAP by 
≥ 5 mmHg. An elevated resting PCWP has been observed in the majority of patients 
with HFpEF,27 and a peak exercise PCWP ≥ 25 mmHg at peak exercise has been 
proposed as a diagnostic criterion for HFpEF.28  Table 3 shows a comparison of the 
inclusion and exclusion criteria for the REDUCE LAP-HF I trial compared to several 
other recent or ongoing trials in HFpEF. 
REDUCE LAP-HF I Trial: Outcome measures 
Patients will be followed for 1 year, and annually every 12 months for a total of 5 years 
after index procedure and implant.  
The key safety outcome measure is major adverse cardiac, cerebrovascular, and renal 
events (MACCRE) through 1 month post-implant (including peri-procedural) defined as 
cardiovascular death, embolic stroke, device- and/or procedure-related adverse cardiac 
or new-onset or worsening of kidney dysfunction (defined as eGFR decrease of > 20 
ml/min/1.73 m2) through 1-month post implant.  
The key effectiveness outcome measure is for a mechanistic effect and is the change 
in supine exercise PCWP at 1 month, as assessed by an independent blinded 
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hemodynamic core laboratory, across the four exercise workload values (20W, 40W, 
60W, and 80W), measured at both the baseline and 1-month follow-up visit. Key 
secondary and additional outcome measures for safety, effectiveness and efficacy are 
detailed in Table 4. 
REDUCE LAP-HF I Trial: Sample Size Determination 
The key effectiveness outcome measure is the change in supine exercise PCWP from 
baseline to 1 month post-procedure. At each of baseline and 1 month, four supine 
exercise PCWP values will be measured (at 20W, 40W, 60W, 80W). The null and 
alternative hypotheses of interest across these four measurements are: 
H0:µI20W –µC20W =0,µI40W –µC40W =0,µI60W –µC60W =0,µI80W –µC80W =0 H1: 
At least one of the following is true: 
µI20W – µC20W ≠ 0, µI40W – µC40W ≠ 0, µI60W – µC60W ≠ 0, µI80W – µC80W≠ 0 
where µIiW and µCiW are the mean change from baseline to 1-month PCWP at iW for 
the IASD System II and control, respectively, where i = 20, 40, 60, 80. 
The assumptions used for the power calculations are generated from historical data 
and data from the pilot study. 
Assuming a mean change in exercise PCWP of -6.0 mmHg for IASD System II and 0.0 
mmHg for control at each of 20W, 40W, 60W and 80W, and assuming a standard 
deviation in PCWP change of 7.2 mmHg in each treatment group at each of 20W, 40W, 
60W and 80W, a sample size of 20 evaluable subjects per treatment group yields 82% 
power to detect a significant beneficial effect of IASD System II over control when 
comparing treatment means using a mixed measures repeated model (MMRM) 
analysis of covariance (ANCOVA), assuming the compound symmetry correlation 
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structure where the pairwise correlations between 20W, 40W, 60W and 80W are 0.8 or 
less. Sample size was calculated using the PASS 14 software (NCSS, LLC, Kaysville, 
Utah). 
	  
REDUCE LAP-HF I Trial:  Analysis populations 
The analysis populations in the trial include intent-to-treat (ITT; all randomized 
patients); per-protocol (subset of ITT with successful implant); and safety (ITT in whom 
an implant of the IASD System II was at least attempted—this is the primary analysis 
set for safety).  
 
REDUCE LAP-HF I Trial: General Statistical Approach 
All statistical tests will be carried out at a two-sided 0.05 level of significance, and all p-
values will be presented as two-sided p-values. Analyses will be carried out using SAS 
version 9.4 or higher. Due to the nature of the study, there will be no imputation for 
missing data; also, it is expected that there will be no dropouts at one-month, the time 
at which the key effectiveness and safety outcome measure data are collected. 
Statistical Approach: Key Effectiveness Outcome Measure 
The primary effectiveness outcome is the change in supine exercise PCWP from 
baseline at 1 month at the up to four levels of exercise (at 20W, 40W, 60W, 80W) 
where baseline and 1 month PCWP measurements are available. Descriptive statistics 
of the change in PCWP at 1 month will be presented for each treatment group for each 
of 20W, 40W, 60W, 80W. Treatments will be compared on change in exercise PCWP 
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across the 4 values using MMRM ANCOVA adjusting for the corresponding baseline 
exercise PCWPs, using a two-sided 0.05 level of significance. 
Statistical Approach: Key Safety Outcome Measure 
The key safety outcome measure is the composite incidence of one or more of the 
following: major adverse cardiac, cerebrovascular embolic, or renal events (MACCRE) 
at 1 month. The analysis on the endpoint of MACCRE at 1 month will be descriptive 
(percentage of patients with MACCRE and two-sided exact confidence interval of the 
percentage based on the binomial distribution for each treatment group). While there is 
no formal hypothesis testing on this endpoint, note that for the investigational arm, it is 
anticipated that the true MACCRE rate in the population is approximately 5%. Under 
this assumption, there is a 92% chance in a sample of size 20 that the observed rate 
will be 10% or less. This analysis will be carried out on the ITT population in whom an 
implant of the IADS System II was at least attempted (i.e., the “Safety Population”) with 
available data (follow-up through one month, or a MACCRE event by 1-month). 
Also for each treatment group, Kaplan-Meier curves and estimates of cumulative 
MACCRE rate at 12 months will be presented for all patients in the ITT population 
regardless of length of follow-up. A two-sided 95% confidence interval of the difference 
between treatments with respect to the Kaplan-Meier estimates of cumulative 
MACCRE rate will be presented. In this analysis, patients not experiencing MACCRE 
will be censored at one month or at last known follow-up, whichever is earlier. 
 
REDUCE LAP-HF I Trial Substudies 
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A sub-study will include an optional CPET evaluation and cardiac MRI in eligible 
patients at baseline and follow up. This sub-study will include selected centers where 
these evaluations are well established. The data from the CPET and images from the 
cardiac MRI will be evaluated by independent core laboratories. Participating sites will 
be provided with detailed instructions from the core labs to standardize the conduct of 
these studies across sites. 
 
REDUCE LAP-HF I Trial: Data collection 
All required data for the trial will be collected on standardized case report forms. All 
protocol-mandated echocardiograms and hemodynamic tracings will be sent to 
independent core laboratories. The echocardiographic core laboratory for this study is 
The Center for Quantitative Echocardiography (University of Pennsylvania, 
Philadelphia, PA) and the hemodynamic core laboratory is Cardiovascular Clinical 
Studies, Inc. (Boston, Massachusetts).  The exercise testing core laboratory is the 
Cardiopulmonary Exercise Testing Core Laboratory, Dept. of Health and Exercise 
Science (Wake Forest University, Winston Salem, North Carolina), and the MRI core 
laboratory is the MRI Core Laboratory, Cardiovascular Clinical Studies, Inc. (Boston, 
Massachusetts). Data management is by Harvard Clinical Research Institute, Boston, 
Massachusetts. 
 
REDUCE LAP-HF I Trial: Data safety monitoring board and Clinical Events 
Committee 
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The separate data-safety-monitoring board (DSMB) and Clinical Events Committee are 
managed by the Clinical Research Organization, Harvard Clinical Research Institute, 
Boston, Massachusetts. 
 
Discussion 
HFpEF, with its increasing prevalence and high morbidity and mortality, is a major 
unmet need in cardiovascular medicine today.1,29,30 We hypothesize that creating an 
appropriately sized left to-right atrial shunt that will allow LA decompression without 
significantly compromising left ventricular filling and forward cardiac output is a rational 
strategy for treating patients with HFpEF, potentially improving symptoms (particularly 
during exertion) and reducing HF hospitalizations. Furthermore, given the device-based 
nature of the treatment, patient non-compliance and polypharmacy are minimized, 
which could be beneficial in these patients who are often elderly and have multiple 
comorbidities. Corvia Medical, Inc. has developed a trans-catheter intracardiac device 
(the InterAtrial Shunt Device [IASD®] System II) that creates an 8 mm permanent 
opening in the septum between the right and left atria of the heart, designed to maintain 
a permanent communication. An early unblinded, single-arm pilot study of the IASD in 
HFpEF has yielded promising results, and a second, larger unblinded, single-arm study 
is ongoing. Although the prior experience with the IASD has been encouraging, a 
randomized controlled trial is necessary to provide further evidence of device efficacy 
and safety. Here we have described the rationale and design of the REDUCE LAP-HF I 
clinical trial of the IASD in patients with HF and LV ejection fraction ≥ 40%, which 
should advance our understanding of the utility of this device in HF.  
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There is currently one other device utilizing similar hemodynamic principles of an atrial 
shunt.31 The V-Wave device (V-Wave Medical; Caesarea, Israel) is an hourglass-
shaped nitinol frame device with three valve leaflets intended to mechanically maintain 
a 5 mm sized unidirectional left-to-right shunt at the level of the atrial septum. The V-
Wave device was successfully implanted in five patients with chronic HFrEF with a 
mean LVEF of 25±6%. At three months follow-up all patients showed clinical 
improvement as evidenced by change to NYHA class II, increased 6-minute walking 
test, reduction in PCWP and NT-pro-BNP, but there were no changes in LVEF, end-
diastolic LV diameter, LA volume, mitral regurgitation grade or right arterial pressure.  
There were no device-related adverse events. 
 
Strengths 
The study described here is the first randomized trial of a device-based therapy for 
lowering LA pressure in patients with HFpEF. Incorporating a randomized evaluation 
with a control arm is important given the potential for a placebo effect, as has been 
demonstrated for other device-based therapies.32 The trial benefits from strict inclusion 
criteria for the diagnosis of HF (requiring both signs/symptoms of HF; and objective 
evidence of LV diastolic dysfunction or LA enlargement; and objective invasive 
hemodynamic evidence of elevated LA pressure). In addition, the trial includes detailed 
hemodynamic assessment during exercise, which is critical given the exercise-related 
symptoms that are so common in HFpEF.  
 
Limitations 
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Given the small sample size, the trial presented here will not be definitive; a larger, 
pivotal trial will be necessary to establish clinical efficacy. However, this first 
randomized evaluation of the IASD system is to establish effectiveness and to inform 
the design of such a pivotal study; mechanistic effect, will provide the impetus to 
proceed with a larger pivotal trial designed to evaluate clinical outcomes related to 
heart failure while avoiding the need for burdensome invasive hemodynamic follow-up 
evaluation.  Finally, while this is designed as a single (patient) blinded study, there is 
opportunity for inadvertent unblinding which could impact the subjective secondary 
outcome measures. However, the key effectiveness outcome measure, changes in 
PCWP across the range of exercise levels, is objective and will be evaluated by a 
blinded core lab. 
  
 
Conclusions 
The initial non-randomized, single-arm clinical trial using the Corvia trans-catheter 
interatrial shunt supports the safety of the implantation procedure, the safety of the 
device itself after implantation, and both hemodynamic and clinical improvements. The 
new trial presently described will the first prospective, multicenter, randomized, and 
single blinded trial to test this strategy and has strong potential to provide important 
data to further advance knowledge of this first-in-class, novel, transcatheter device-
based therapy for HFpEF. 
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REDUCE LAP-HF I Trial: Sources of Funding 
The study is funded entirely by Corvia Medical, Inc. (Tewksbury MA) 
 
Disclosures 
JK is an employee of Corvia Medical, Inc., the sponsor of the REDUCE LAP-HF I 
clinical trial. There are no other disclosures or conflicts of interest. 
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FIGURE LEGENDS 
Figure 1: Corvia Medical, Inc. IASD® System II device.  
Figure 2: Corvia Medical, Inc. IASD® System II delivery system. 
Figure 3: Implant after placement in the interatrial septum. 
Figure 4: Patient flow through the trial. 
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Table 1: Pharmacological Treatment for Stage C HFpEF—AHA/ACC Guideline 
Recommendations 
 
CLASS I 
Systolic and diastolic blood pressure should be controlled according to published 
clinical practice guidelines (Level of Evidence: B) 
Diuretics should be used for relief of symptoms due to volume overload. (Level of 
Evidence: C) 
 
CLASS II 
Coronary revascularization for patients with CAD in whom angina or demonstrable 
myocardial ischemia is present despite GDMT (Level of Evidence: C) 
Management of AF according to published clinical practice guidelines for HFpEF to 
improve symptomatic HF (Level of Evidence: C) 
Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF 
ARBs might be considered to decrease hospitalizations in HFpEF (Level of Evidence: 
C) 
 
CLASS III: No Benefit 
Nutritional supplementation is not recommended in HFpEF (Level of Evidence: C) 
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Table 2: Inclusion and exclusion criteria for the REDUCE LAP-HF I trial 
Candidates for the study must meet ALL of the following inclusion criteria:  
1. Chronic symptomatic heart failure (HF) documented by the following:  
a. New York Heart Association (NYHA) class III/ambulatory class IV symptoms 
(Paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate 
exertion) at screening visit; or signs (Any rales post cough, chest x-ray 
demonstrating pulmonary congestion,) within past 12 months; AND   
b. ≥ One hospital admission for which HF was a major component of the 
hospitalization, or an emergency department visit with IV treatment for HF 
within the 12 months prior to study entry; OR an NT-pro BNP value > 50 
pmol/L (>425 pg/ml) in normal sinus rhythm, >150 pmol/L (>1265 pg/ml) in 
atrial fibrillation, or a BNP value > 100 pg/ml in normal sinus rhythm, > 250 
pg/ml in atrial fibrillation within the past 3 months.   
2. Ongoing stable GDMT HF management and management of potential comorbidities 
according to the 2013 ACCF/AHA Guidelines for the management of Heart Failure 
(with no significant changes [>100% increase or 50% decrease], excluding diuretic 
dose changes for a minimum of 4 weeks prior to screening) that is expected to be 
maintained without change for 6 months.  
3. Age ≥ 40 years old  
4. Site determined LV ejection fraction ≥ 40% within the past 3 months, without 
previously documented ejection fraction <30%.  
5. Site determined elevated LA pressure with a gradient compared to right atrial 
pressure documented by end-expiratory PCWP during supine ergometer exercise ≥ 
25mm Hg, and greater than right atrial pressure by ≥ 5 mm Hg.  
6. Site determined echocardiographic evidence of diastolic dysfunction documented by 
one or more of the following:   
a. LA diameter > 4 cm; or   
b. LA volume index > 28 ml/m2 or  
c. Lateral e’ <10 cm/s; or  
d. Septal e’ <8 cm/s; or  
e. Lateral E/e’ >10 ; or  
f. Septal E/e’ > 15   
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7. Subject has been informed of the nature of the study, agrees to its provisions and 
has provided written informed consent, approved by the IRB or EC   
8. Subject is willing to comply with clinical investigation procedures and agrees to return 
for all required follow-up visits, tests, and exams   
9. Trans-septal catheterization and femoral vein access is determined to be feasible by 
site principal interventional cardiology investigator   
Candidates for this study will be excluded if ANY of the following conditions are 
present:  
1. MI and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 
months, or current indication for coronary revascularization 
2. Cardiac resynchronization therapy initiated within the past 6 months 
3. Severe heart failure defined as one or more of the below: 
a. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF; 
b. Cardiac index < 2.0 L/min/m2 
c. Inotropic infusion (continuous or intermittent) within the past 6 months 
d. Patient is on the cardiac transplant waiting list 
4. Inability to perform 6 minute walk test (distance < 50 m), OR 6 minute walk test > 
600m 
5. Known clinically significant un-revascularized coronary artery disease, defined as: 
epicardial coronary artery stenosis associated with angina or other evidence of 
coronary ischemia. 
6. History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or 
pulmonary emboli within the past 6 months 
7. Known clinically significant untreated carotid artery stenosis. 
8. Presence of significant valve disease defined by the site cardiologist as: 
a) Mitral valve regurgitation defined as grade ≥ 3+ MR 
b) Tricuspid valve regurgitation defined as grade ≥ 2+ TR; 
c) Aortic valve disease defined as ≥ 2+ AR or > moderate AS 
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9. Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, constrictive 
pericarditis, cardiac amyloidosis or other infiltrative cardiomyopathy (e.g. 
hemochromatosis, sarcoidosis) 
10. Subject is contraindicated to receive either dual antiplatelet therapy or warfarin 
(analogue); or has a documented coagulopathy 
11. Atrial fibrillation with resting HR > 100 BPM 
12. Arterial oxygen saturation < 95% on room air 
13. Significant hepatic impairment defined as 3X upper limit of normal of 
transaminases, total bilirubin, or alkaline phosphatase 
14. Right ventricular dysfunction, defined by the site cardiologist as 
a. More than mild RV dysfunction as estimated by TTE; OR 
b. TAPSE < 1.4 cm; OR 
c. RV size ≥ LV size as estimated by TTE; OR 
d. Echocardiographic or clinical evidence of congestive hepatopathy; OR 
e. Evidence of RV dysfunction defined by TTE as an RV fractional area change 
< 35%; 
15. Resting right atrial pressure > 14 mmHg 
16. Evidence of pulmonary hypertension with PVR > 4 Wood units 
17. Chronic pulmonary disease requiring continuous home oxygen, OR hospitalization 
for exacerbation in the 12 months prior to study entry, OR significant chronic pulmonary 
disease defined as FEV1 < 50% predicted, or in the opinion of the investigator 
18. Currently participating in an investigational drug or device study. Note: trials 
requiring extended follow-up for products that were investigational but have since 
become commercially available are not considered investigational trials 
19. Life expectancy less than 12 months for non-cardiovascular reasons 
20. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation 
21. Known or suspected allergy to nickel 
22. Fertile women 
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23. Currently requiring dialysis; or estimated-GFR <25ml/min/1.73 m2 by CKD-Epi 
equation 
24. Systolic blood pressure >170 mm Hg at screening 
25. Subjects with existing s. Subjects with a patent foramen ovale (PFO), who meet 
PCWP criteria despite the PFO, are allowed. 
26. Subjects on immunosuppression or systemic steroid treatment (>10 mg 
prednisone/day). 
27. Severe obstructive sleep apnea not treated with CPAP or other measures 
28. Severe depression and/or anxiety 
29. In the opinion of the investigator, the subject is not an appropriate candidate for the 
study 
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Table 3. Inclusion Criteria of Recent/Ongoing Heart Failure with Preserved Ejection Fraction Trials with Comparison to 
REDUCE LAP-HF I 
 
Inclusion criteria REDUCE LAP-HF I PARAGON SOCRATES-Preserved NEAT TOPCAT 
Primary inclusion 
criteria: 
hospitalization for 
HF vs. BNP 
Prior hospitalization for 
HF or elevated BNP 
Prior hospitalization for 
HF or elevated BNP 
Recent hospitalization 
for HF and elevated 
BNP 
Prior hospitalization for HF 
or elevated BNP or 
alternative objective 
evidence of HF* 
Prior hospitalization with 
HF or elevated BNP** 
NYHA class III or ambulatory IV II or III II, III, or IV II, III, or IV II, III, or IV 
Age ≥ 40 ≥ 50† ≥ 18 ≥ 50 > 50 
LVEF cut-off ≥ 40% > 45% ≥ 45% ≥ 50% ≥ 45% 
Natriuretic 
peptides 
BNP > 100 pg/ml  
(> 250 pg/ml if AF) 
NTproBNP > 425 pg/ml  
(> 1265 pg/ml if AF) 
NTproBNP > 300 pg/ml 
(> 900 pg/ml if AF) 
BNP ≥ 100 pg/ml 
(≥ 200 pg/ml if AF) 
NTproBNP ≥ 300 pg/ml 
(≥ 600 pg/ml if AF) 
BNP > 200 pg/ml 
NTproBNP > 400 pg/ml 
BNP > 100 pg/ml 
NTproBNP > 360 pg/ml 
Echocardiographic 
criteria 
Increased LA size or LV 
diastolic dysfunction 
required (multiple 
possible criteria) 
Increased LA size or 
LV hypertrophy 
required (multiple 
possible criteria) 
Increase LA size 
required (multiple 
criteria including LA 
volume, LA area, or LA 
diameter) 
Besides LVEF ≥ 50%, 
echocardiographic criteria 
were only required as one 
of the possible eligibility 
criteria 
None besides LVEF ≥ 45% 
Invasive 
hemodynamic 
criteria 
PCWP at rest or with 
exercise > 25 mmHg 
required in all patients; 
PCWP > RA pressure 
by ≥ 5 mmHg 
None None Invasive hemodynamic 
criteria were included in 
eligibility criteria but were 
not required for enrollment 
None 
Primary endpoint Key effectiveness 
measure: change in 
exercise PCWP;  
key safety measure: 
major adverse cardiac, 
cerebrovascular, 
embolic, or renal events 
Composite of CV death 
and total HF 
hospitalizations 
Co-primary endpoints: 
(1) change in 
NTproBNP; and (2) 
change in LA volume 
Accelerometer-assessed 
physical activity 
Composite of CV death, HF 
hospitalization, or aborted 
cardiac arrest 
*In NEAT, alternate criteria besides prior hospitalization for HF or elevated BNP included: (1) elevated LV filling pressures on invasive hemodynamic 
testing or (2) echocardiographic evidence of diastolic dysfunction, LV hypertrophy, and/or elevated LV filling pressures (at least 2 criteria were required). A 
complete description of the specific invasive hemodynamic and echocardiographic criteria is listed in Zakeri et al. Circ Heart Fail 2015;8:221-228. 
**In TOPCAT, heart failure only had to be one of the reasons for hospitalization (not the primary reason for hospitalization).  
†In PARAGON, the age cutoff initially was > 55 years but has since been amended to an age cutoff of > 50 years.  
HF = heart failure; BNP = B-type natriuretic peptide; NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; AF = atrial fibrillation; 
NTproBNP = N-terminal pro-B-type natriuretic peptide; LA = left atrial; PCWP = pulmonary capillary wedge pressure; RA= right atrial; CV = cardiovascular
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Table 4: Additional outcome measures for safety and effectiveness  
Safety related outcome measures: 
1. Major adverse cardiac events through 12-months 
2. All serious adverse events (SAEs) through 12-months 
3. All-cause mortality, CV mortality and heart failure related mortality through 12-
months 
4. Newly acquired persistent or permanent AF or atrial flutter through 12-months 
5. Implant embolization and clinically significant device migration through 12-months. 
6. Systemic embolic events through 12-months. 
7. Increase in RV size/decrease in RV function through 12-months 
8. The need for implant removal or occlusion of the implant. 
Efficacy related outcome measures: 
1. All-cause, and heart failure related hospitalizations/emergency department visits with 
IV treatment for HF; and number of hospitalization days, ICU days through 12 months 
2. Treatment for outpatient worsening of heart failure 
3. Days alive, and not-hospitalized through 12-months 
4. Change in blinded Investigator assessed NYHA classification between baseline and 
12 months. 
5. Change in 6MWT distance between baseline and 12 months 
6. Assessment of shunt dimensions and flow at 12 months 
7. Changes in resting and exercise PA pressures and CI between baseline and 1 
month as assessed by an independent blinded hemodynamic core laboratory. 
8. Change in BNP and/or NT-pro-BNP, and MR-ANP between baseline and at 12 
months 
9. Changes in LA, LV dimensions, volume, and function, between baseline and 12 
months assessed by an independent echocardiographic core laboratory 
10. Changes in RA, LA, LV and RV dimensions, volume, and function between 
baseline and 12 months assessed by a cardiac MRI core laboratory (Sub-study only) 
11. Change in CPET parameters (including exercise time) between baseline and 12 
months as assessed by an independent blinded CPET core laboratory (Sub-study only) 
12. Change in diuretic medications between baseline and 12 months 
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Figure 1: Corvia Medical, Inc. IASD® System II device.  
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Figure 2: Corvia Medical, Inc. IASD® System II delivery system. 
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Figure 3: Implant after placement in the interatrial septum. 
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Figure 4: Patient flow through the trial. 
 
 
